Aurigene develops its own portfolio of best-in-class differentiated drug candidates, and partners with different pharma companies. Aurigene’s ability to come up with differentiation strategies in Oncology and Inflammation, flexible business model either early-stage licensing or option-based arrangements, and the head-start it gives our partners in targets of their interest, adds value.Our strengths are validated by the success of the 5 programs out of 8 initiated over the last 7 years that have reached IND stage.

Please click on the link to get more details of our current partnering pipeline.